Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs MPLX LP (MPLX) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs MPLX LP — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while MPLX LP trades at $59.9 (market cap $60.12B). The key difference: MPLX LP is far larger — about 6.4× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and MPLX LP pays a 7.26% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

BIOMPLX
Market Cap
$9.43B$60.12B
Sector
HealthTechnology
52-Week High
$356.25$60.51
52-Week Low
$241.71$47.80
Enterprise Value
$9.18B$85.22B
Dividend Yield
7.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories (BIO) trades at $362.08, up 2.13% daily, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, Q2 2026 earnings beat estimates with EPS of $2.62 versus $1.75 expected, and revenue remains stable around $2.6 billion. Net income turned positive in 2025 after prior losses, with a current net margin of 29.41%. Analyst consensus is Buy with a $350 price target, and institutional holdings increased, as noted by Amundi's 1,763.4% stake growth per SEC filing on August 5, 2026.

Outlook is cautiously optimistic with solid earnings recovery and institutional support, but risks include high P/E of 43.39, potential overvaluation, and reliance on academic research markets. Investors should weigh strong profitability against valuation concerns and monitor upcoming Q3 earnings for sustained growth.

MPLX LP

MPLX trades at $59.94, up 2.11% today, with a bullish technical signal from moving averages and a consensus analyst price target of $61.50. The company reported strong 2025 results with $11.47B revenue and $4.91B net income, though recent quarterly earnings have missed expectations. A recent $2.25B senior notes offering (PRNewsWire, Aug 10, 2026) supports growth initiatives, while a 7.3% dividend yield attracts income investors.

Outlook remains positive given fee-based revenue stability and growth projects, but risks include execution challenges from higher capital spending and leverage. Analyst sentiment is strongly bullish with no sell ratings, though investors should monitor earnings consistency and debt levels amid volatile energy markets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About MPLX LP

MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.

Read more on MPLX